SPARKLE: a new spark in treating oligorecurrent prostate cancer: adding systemic treatment to stereotactic body radiotherapy or metastasectomy: key to long-lasting event-free survival?

Overview of attention for article published in BMC Cancer, December 2022

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (74th percentile)
High Attention Score compared to outputs of the same age and source (89th percentile)

So far, Altmetric has seen 8 X posts from 7 X users, with an upper bound of 3,469 followers.

RT @KatoRans: Proud to present the protocol of the SPARKLE Trial published in @BioMedCentral Oligorecurrent prostate cancer: adding syste…

RT @KatoRans: Proud to present the protocol of the SPARKLE Trial published in @BioMedCentral Oligorecurrent prostate cancer: adding syste…

RT @KatoRans: Proud to present the protocol of the SPARKLE Trial published in @BioMedCentral Oligorecurrent prostate cancer: adding syste…

RT @KatoRans: Proud to present the protocol of the SPARKLE Trial published in @BioMedCentral Oligorecurrent prostate cancer: adding syste…

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 4 additional X posts.